Skip to content
Catalyst

PapersPMID:33460048

Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.

The Cochrane database of systematic reviews2021The record ↗

  1. Finding, very limited evidenceno difference foundHamilton Depression Rating Scale (HDRS) total score

No finding here moved its endpoint.

What did not

1 findingHow to read these marks →
  • “There is no clear evidence of an effect on anxiety (MD -0.20, 95% CI -4.84 to 4.44; 1 trial, 19 participants; change scores; Hamilton Anxiety Scale (HAM-A; scored from 0 to 56); very low-certainty evidence) or depression (MD 2.80, 95% CI -0.09 to 5.69; 1 trial, 19 participants; change scores; Hamilton Depression Scale (HAM-D; scored from 0 to 52); very low-certainty evidence) in analyses comparing IR methylphenidate with placebo.”
    Study
    RCT
    Participants
    19
    Effect
    2.8 mean difference, 95% CI −0.09 to 5.69
    Population
    adults with ADHD, immediate-release methylphenidate versus placebo; secondary outcome (depression)

Study record

Design
meta-analysis
Species
human
Population
adults with ADHD (outpatients, addiction-treatment inpatients, and an intensive outpatient programme for cocaine dependence); 10 RCTs, 497 participants
Participants
497
Comparator
an active treatment / placebo
Duration
not reported
Endpoints measured
9